Patents Assigned to PanOptica, Inc.
  • Ocular formulations for drug-delivery to the posterior segment of the eye
    Patent number: 10307404
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: June 4, 2019
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Ocular formulations for drug-delivery to the posterior segment of the eye
    Patent number: 10092549
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 9, 2018
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Ocular formulations for drug-delivery and protection of the anterior segment of the eye
    Patent number: 9814702
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: November 14, 2017
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Ocular formulations for drug-delivery and protection of the anterior segment of the eye
    Patent number: 9623011
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: April 18, 2017
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Ocular formulations for drug-delivery to the posterior segment of the eye
    Patent number: 9446026
    Abstract: The present invention relates to topical formulations comprising a compound of the following formula: for treating ocular neovascularization. The Compound-I is present in a solution or a suspension in about 0.005% to about 5.0% w/v, such that the solution or suspension delivers the compound at the posterior segment of the eye for inhibiting VEGF in the retina and/or the choroid.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 20, 2016
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax